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Abstract
Objective: To determine the frequency of peptic ulcer disease in patients on nonsteroidal
anti-inflammatory drugs (NSAID).
Methods: Record of eight hundred and twenty consecutive patients undergoing upper gastrointestinal (GI) endoscopy; from January 1998 to December 2000 were reviewed. The endoscopic diagnosis varied from gastritis, peptic ulcer to duodenitis. The use of NSAID was documented by reviewing medical records of patients with peptic ulcer.
Results: Peptic ulcers were found in 43% (353/820) patients. NSAID associated peptic ulcers were
identified in 14.7% (52/353) patients. Diclofenac and aspirin were most common NSAIDs associated with peptic ulcers in 32.7% (17/52) and 30.7% (16/52) patients, respectively. Duodenal ulcer was
more common than gastric ulcer 65.3% (34/52) and 42.3% (22/52), respectively. H. pylori infection
was present in 46% (24/52) of the cases. NSAIDs treatment and / or H. pylori infection compared
to non NSAIDs and non H. pylori infected peptic ulcer disease were significantly
associated
with gastric ulcer (p = 0.004) and duodenal ulcer (p = 0.009) respectively.
Conclusion: NSAID-associated peptic ulcer disease is common in Pakistan and most frequently
associated with gastric and duodenal ulcer. H. pylori infection is common in association with NSAID
related peptic ulcers (JPMA 56:218;2006).

Introduction
Non-steroidal anti-inflammatory drugs
(NSAIDs) are widely used for the treatment of pain
and inflammation worldwide.1 They are available
over the counter with widespread use for various
indications. The use of NSAID is associated with
well-recognized risks of gastrointestinal toxicity.2
The drugs commonly associated with gastroduodenal
ulceration include NSAIDs, steroids, antibiotics and
chemotherapy agents. Most peptic ulcers not due to
Helicobacter pylori (H. pylori) are caused by
NSAIDs.3 Peptic ulcer disease symptoms vary from
dyspeptic symptoms to haematemesis and malaena. It
may prove fatal in some patients. The various
mechanisms of NSAID induced gastric injury
include: a) damage of the gastric epithelium by intracellular accumulation of these drugs in an
ionized
state, b) reducing the hydrophobicity of the mucous
gel layer by changing the action of
surfaceactive phospholipids, c) suppression of the
prostaglandin synthesis, d) injury due to neutrophils
adherence to the endothelium of gastric microcirculation.4-7 Established risk factors for NSAIDs
associated peptic ulcer disease include advanced age,
female gender, past history of peptic ulcer, non-selec-
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tive NSAIDs, concomitant use of anticoagulants or
corticosteroids, H. pylori infection and heavy consumption of alcohol.8 The risk of gastrointestinal
bleeding increases steeply with age, and the excess
risk from nonaspirin NSAIDs is much higher in the
elderly than in young subjects, even when the relative
risk is assumed to remain constant with age.9 The
excess risk in women is attributed to their age >65
years, higher dose of NSAIDs per kilogram body
weight and much steeper dose response curve in
women than in men.10 H. pylori and NSAIDs damage
the stomach by different mechanisms. However,
neutrophil-induced mucosal injury might be a
common pathogenetic pathway shared by these two
factors. This is consistent with the finding that H.
pylori-induced neutrophil infiltration is associated
with an increased risk of ulcers in chronic NSAIDs
users.11 As the rate of H. pylori infection is falling, the
proportion of NSAIDs related-peptic ulcer has
risen.12 Although no NSAID is totally safe, it has
been demonstrated that NSAIDs may be ranked
according to relative GI toxicity.10 Depending on the
plasma levels and the half-life of the NSAIDs, the
risk is short-lived with ibuprofen than piroxicam with
a long plasma half-life.13,14 This is attributed to the
differential inhibition by the NSAIDs of the 2
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isoenzymes involved in the synthesis of
prostaglandins, cyclo-oxygenase-1 (COX-1) and
cyclo-oxygenase-2 (COX-2). Improved GI safety is
observed with drugs that spare COX-1, the
isoenzyme responsible for gastroprotection. In
contrast, the more toxic drugs demonstrate greater
COX-1 inhibition.15,16 Alcohol consumption of > 5
drinks at a time increased the risk significantly above
that seen in moderate drinkers and non-drinkers.10
The aim of this study was to determine the frequency
of NSAIDs related-peptic ulcer disease in dyspeptic
patients undergoing upper gastrointestinal endoscopy
in a tertiary care hospital.

Patients and Methods
This retrospective study was conducted at Aga Khan
University Hospital, Karachi, Pakistan. Medical
records of 820 consecutive patients
undergoing
upper gastrointestinal (GI) endoscopy from January
1998-December 2000 were reviewed who attended
gastroenterology department and had endoscopic
diagnosis of gastritis, peptic ulcers or duodenitis. The
history of NSAIDs use was collected by reviewing
the patient’s medical record with age, sex, previous
diagnosis, current indication, dosage and duration of
NSAID use. The risk factors
associated with peptic ulcer disease such as smoking, alcoholism, pan
eating and tobacco chewing with concomitant use of
medications such as
anticoagulants and
corticosteroid were also noted. The endoscopic
lesions were classified into gastritis, peptic ulcer, and
duodenitis. Peptic ulcer was defined as a break of
about 3mm in the mucosal surface and then categorized according to site i.e., fundus, corpus, antral,
pylorus and duodenal ulcer as proximal (D1) or distal
(D2). Rapid urease test (CLO test) and histopathology results were noted.
Results were expressed as mean standard deviation,
median with range for all continuous variables (age,
dose etc) and number (percentage) for categorical
data (e.g. gender, etc.). However,
univariate
analysis was performed by using Pearson's Chisquare, Fisher-exact test and the difference in mean
was evaluated by independent sample T test where
ever appropriate. A p-value less than 0.05 was considered statistically significant. Statistical interpretation
of data was performed using the
computerized
software program SPSS version 10.0.

Results
The frequency of various NSAIDs used by the patients
and associated with peptic ulcer is shown in
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Table 1.
The most common indication for prescribing
NSAID was arthritis in 40% (21/52) and muscular
aches in 36.5% (19/52) patients (Table 1).
Duration of NSAID use varied from less than
1 month for 52% (27/52) to greater than 1 month for
48% (25/52) patients. Risk factors for NSAID related
peptic ulcer were noted in only 31% (16/52) patients.
Smoking and concomitant steroid therapy were the
commonest risk factors (Table 1). There were no
Table 1 NSAID-related peptic ulcer disease clinical details,
risk factors and associated diseases.
Total No.
Sex:
Male
Female
Age:
Range( years)
Male
Mean
Female
Mean
Risk factors:
1. Smoking
2. Corticosteriods
therapy
3. Alcoholism
4. Pan eating
Disease
1. No co-morbids
2. Chronic liver
disease
3. Cancer
4. Bleeding
disorder
5. Tuberculosis
NSAID used
Diclofenac
Aspirin
(enteric coated)
Piroxicam
Ponstan
Indmethacin
Ibuprofen
Flubiprofen
Naproxen
Indication for
NSAID use
1. Arthritis
2. Muscular
aches
3. Orthopedics
problems
4. Fever

NSAID
52

Non-NSAID
301

30
22

204
97

16-80

16-90

59 + 13.48

48 + 16.78

54 + 15.83

48 + 15.42

9 (17.3%)
5 (9.6%)

44 (14.6%)
17 (5.6%)

1 (1.9%)
1 (1.9%)

13 (4.3%)
9 (3%)

45 (86.5%)
5 (9.6%)

239 (79.4%)
40 (13.3%)

1 (1.9%)
1 (1.9%)
-

1 (1.9%)
7 (2.3%)

17 (33%)
16 (31%)
5 (10%)
4 (8%)
3 (5%)
3 (5%)
2 (4%)
2 (4%)

21 (40 %)
18 (35 %)
9 (17%)
4 (8%)
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Table 2.
Site of Peptic ulcer

Gastric ulcer
Gastric ulcer + Duodenal ulcer
Duodenal ulcer
None
Gastric Ulcer
Fundus
Body
Antrum
Pylorus

Duodenal ulcer
D1
D2
D1 + D2
HP: Helicobaoter Pylori

NSAID
H.P
Non H.P
Infection
Infection
(n=24)
(n=28)
6 (25%)
2 (8%)
16 (67%)

11 (39%)
3 (11%)
13 (46%)
1 (4%)

1 (13%)
4 (50%)
3 (37%)

1
4
6
3

16 (89%)
2 (11%)

(29%)
(29%)
(43%)
(21%)

16 (100%)
-

P-value

0.379

0.566

0.487

Non-NSAID
H.P
Non H.P
Infection
Infection
(n=175)
(n=126)
34 (20%)
12 (7%)
123 (25%)
6 (3%)

48
9
68
1

(38%)
(7%)
(54%)
(1%)

3 (7%)
15 (33%)
23 (50%)
5 (10%)

6 (11%)
18 (32%)
23 (50%)
10 (17%)

122 (90%)
6 (4%)
7 (5%)

67 (87%)
4 (5%)
6 (8%)

P-value

0.002

0.612

0.724

Table 3. Univariate analysis of NSAID and or H. pylori infection associated peptic ulcer disease with Non-NSAID
and H. pylori negative peptic ulcer disease.
Non-NSAID and non H. pylori infection
Glastric ulcer

NSAID and H. pylori infection
+

-

69 (30%)

159 (70%)

+

57 (46%)

68 (54%)

P value

0.004

Duodenal ulcer
-

49 (46%)

58 (54%)

+

77 (31%)

169 (69%)

NSAIDs associated peptic ulcers (Table 1). Of 820
patients, 43% (353/820) had peptic ulcer disease,
15% (52/353) had NSAID-related and 85% (301/353)
patients had non-NSAID use peptic ulcer. In NSAIDrelated peptic ulcer disease 57.6% (30/52) were males
and 42.4% (22/52) were females (Table 1). Their age
ranged from16-80 years. The mean age of male
patients with NSAID-related peptic ulcer was
59 ± 13.48 years and in females 54 ± 15.83 years.
NSAID related gastric ulcer and duodenal ulcer when
compared with non-NSAID related gastric ulcer and
duodenal ulcer (p= 0.260) and (p= 0.464) respectively. H. pylori were positive on rapid urease test or
histopathology in 46% (24/52) of NSAID- related
peptic ulcers and negative in 54% (28/52). In nonNSAID related peptic ulcers, H. pylori were positive
in 58% (175/301) and negative in 42% (126/301).
NSAID-related peptic ulcer disease with or without
H. pylori infection when compared with
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0.009

non-NSAID related peptic ulcer disease and without
H. pylori infection (p=0.004) for gastric ulcer and
(p=0.009) for duodenal ulcer (Table 3).

Discussion
NSAIDs and H. pylori infection are two most
important independent factors in peptic ulcer disease.
Their relative frequency as the cause of peptic ulcer
varies and is partly related to the use of NSAIDs and
frequncy of H. pylori infection in a population. The
use of NSAIDs and H. pylori infection is both
common in elderly population.17 There has been an
increase in admissions due to peptic ulcer
haemorrhage and perforation among elderly people
attributed to NSAIDs and low-dose aspirin use.12 In
USA, prescribed NSAIDs account for about 25% of
all reported adverse drug reactions. An estimated
16500 patients with arthritis die every year from the
gastrointestinal related side effects of NSAIDs.2 It is
now recognized that NSAIDs induced gastrointestinal
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toxicity, is primarily due to inhibition of gastric
mucosal prostaglandin synthesis, which subsequently
impairs the cytoprotective factors. Development of
highly selective cyclo-oxygenase (COX)-2 inhibitors
has followed better understanding of the mechanisms
involved in NSAIDs mediated damage of the
stomach.18
In this study, low dose aspirin therapy and
diclofenac were equally common as NSAIDs
associated with peptic ulcers. This is consistent with
previous studies and reflects that no dose is safe from
gastrointestinal toxicity.12 However, among NSAIDs,
diclofenac has been considered to be at the safer end
of the spectrum for gastrointestinal (GI) risk on
account of its short half-life.10 NSAIDs were found to
be commonly prescribed for arthritis and almost
equally for nonspecific symptoms. The various risk
factors and conditions that have an additive effect on
the gastrointestinal toxicity of NSAIDs were not
prominent in our patients. However, patients with
NSAIDs related-peptic ulcer disease did have a
higher mean age, which is an established
risk factor (Table 1). Peptic ulcers associated with
NSAIDs were seen in the the first part of duodenum
followed by gastric body. This might be attributed to
high incidence of H. pylori infection in these patients.
In a local prospective study regarding risk factors
associated with peptic ulcer disease, 80% had duodenal ulcer (DU) and 20% gastric ulcer (GU) with a
DU: GU ratio of 4:1.19 Intake of NSAIDs was the
second major risk factor in 40% of PUD patients, particularly associated with GU (50%).19 In another
study those taking a relatively higher dose of aspirin
(300mg) or soluble aspirin complained of more
symptoms. However, endoscopy did not show a corresponding rise in mucosal injury in them.20 NSAID
related-peptic ulcers were associated with H. pylori
infection in 46 % of our cases. Also, H. pylori infection was more commonly associated with NSAIDs
related duodenal ulcer than gastric ulcer in this study.
This may be consistent with an increased incidence of
H. pylori infection in our part of the world. However,
a larger population based study is required to confirm
these findings, as the sample size was small.
The clinical implications of this study are that
as none of these non-selective NSAIDs are devoid of
gastrointestinal toxicity, it would be safer to restrict
their use in nonspecific symptoms. In elderly, options
available are between choosing an NSAID with
known low incidence of GI toxicity in a lowest
effective dose. If a non-selective NSAID cannot be
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stopped, concomitant use of a proton pump inhibitor
(PPI) or misoprostol will reduce the incidence of
gastric and duodenal ulcer.21 NSAID related peptic
ulcer disease was found to be common with or
without concomitant H. pylori infection in our study.
There was a statistically significant association of
NSAID-related peptic ulcer disease with or without
H. pylori infection as compared to non-NSAID and
non-H. pylori peptic ulcer disease. It is still unclear
whether H. pylori infection plays a synergistic role
with NSAIDs in causing peptic ulcer. A recent
meta-analysis showed H. pylori infection increased
the risk of ulcers in NSAID users to 3.5 times that of
non-infected NSAID users.22 There are studies both
in favour of and against eradicating H. pylori infection that reduces the risk of ulcer in chronic NSAID s
users.23-25 In conclusion, there is a relatively high
incidence of NSAID associated peptic ulcers and they
are equally common with or without concomitant H.
pylori infection.
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